Onsdag 28 Oktober | 18:58:57 Europe / Stockholm

All ägardata du vill ha finns i Holdings!

BONESUPPORT Q3 - Surprising on US sales and EBIT

2024-10-25 10:23:00

Redeye increases its fair value range following a closer look at the report. We were positively surprised by higher US CERAMENT G sales (ahead of any meaningful trauma indication contribution) and higher EBIT than we estimated. We make minor changes to our estimates on all time horizons and lower our WACC following a review of BONESUPPORT’s qualities.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/